Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance

Sheren Younes; Shuchun Zhao; Sushma Bharadwaj; Alicia Palomino Mosquera; Diane Libert; Andrew Johnsrud; Robbie G Majzner; David B Miklos; Matthew J Frank; Yasodha Natkunam

doi:10.1016/j.modpat.2023.100256

Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance

Mod Pathol. 2023 Oct;36(10):100256. doi: 10.1016/j.modpat.2023.100256. Epub 2023 Jun 28.

Affiliations

¹ Department of Pathology, Stanford University School of Medicine, Stanford, California.
² Department of Medicine, Stanford University School of Medicine, Stanford, California.
³ Department of Pathology, Stanford University School of Medicine, Stanford, California. Electronic address: yaso@stanford.edu.

PMID: 37391168
DOI: 10.1016/j.modpat.2023.100256

Abstract

CD58 or lymphocyte function-associated antigen-3, is a ligand for CD2 receptors on T and NK cells and is required for their activation and target cell killing. We recently showed a trend toward higher frequency of CD58 aberrations in patients with diffuse large B-cell lymphoma (DLBCL) who progressed on chimeric antigen receptor-T-cell treatment compared with those who responded. Given that CD58 status may be an important measure of T-cell-mediated therapy failure, we developed a CD58 immunohistochemical assay and evaluated CD58 status in 748 lymphomas. Our results show that CD58 protein expression is downregulated in a significant proportion of all subtypes of B-, T-, and NK-cell lymphomas. CD58 loss is significantly related to poor prognostic indicators in DLBCL and to ALK and DUSP22 rearrangements in anaplastic large-cell lymphoma. However, it is not associated with overall or progression-free survival in any of the lymphoma subtypes. As eligibility for chimeric antigen receptor-T-cell therapy is being extended to a broader spectrum of lymphomas, mechanisms of resistance, such as target downregulation and CD58 loss, may limit therapeutic success. CD58 status is therefore an important biomarker in lymphoma patients who may benefit from next-generation T-cell-mediated therapies or other novel approaches that mitigate immune escape.

Keywords: CAR-T; CD58; expression; lymphoma; resistance.